Skip to main content

Catalyst Calendar

Scope

Wed, Sep 23, 2026

1 updates
ORKA
7:00 AM

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A

Interim Data • Phase 2Interim data Wed, Sep 23, 2026orukatx.com

Wed, Sep 9, 2026

1 updates

Mon, Aug 24, 2026

1 updates
ORKA
4:01 PM

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis

orukatx.com

Mon, Aug 10, 2026

1 updates